Literature DB >> 18336244

Intimal hyperplasia in murine models.

David Y Hui1.   

Abstract

The most commonly used procedures to induce arterial injury in mice are carotid artery ligation with cessation of blood flow and mechanically-induced denudation of endothelium in the carotid or the femoral arteries. Both procedures result in neointimal hyperplasia after two to three weeks. A survey of various inbred strains of mice shows that strain-specific differences in susceptibility to injury-induced neointimal hyperplasia are different than those for susceptibility to diet-induced atherosclerosis, with strains identified as susceptible to both neointimal hyperplasia and atherosclerosis, resistant to both, susceptible to atherosclerosis but resistant to neointimal hyperplasia, or resistant to atherosclerosis but susceptible to neointimal hyperplasia. Inflammatory cells such as T and B lymphocytes, which are contributory to atherosclerosis, are protective against injury-induced neointimal hyperplasia. In contrast, the infiltration of monocytes into the site of injury and their differentiation to macrophages favor neointimal hyperplasia similar to their pathogenic role in atherosclerosis. The regulatory role of lymphocytes and macrophages in neointimal hyperplasia is related to the production of cytokines such as interferon-gamma and tumor necrosis factor-alpha, respectively. Interestingly, inducible nitric oxide synthase (iNOS) activity appears to inhibit neointimal hyperplasia in the endothelial denudation model but contributes to neointimal hyperplasia when arterial injury is induced by periadventitial cuff placement. The difference appears to be due to the time required for endothelial recovery and the participation of inflammatory cells. Thus, although arterial injury-induced neointimal hyperplasia results in similar vascular occlusion as progressive atherosclerosis, the pathology and mechanism of the two disease processes are quite different.

Entities:  

Mesh:

Year:  2008        PMID: 18336244      PMCID: PMC2829189          DOI: 10.2174/138945008783755601

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  77 in total

1.  T lymphocytes inhibit the vascular response to injury.

Authors:  G K Hansson; J Holm; S Holm; Z Fotev; H J Hedrich; J Fingerle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

Review 2.  Regulation of smooth muscle cell growth in injured artery.

Authors:  A W Clowes; M M Clowes; J Fingerle; M A Reidy
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

3.  Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.

Authors:  U C Garg; A Hassid
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

4.  Balloon catheter de-endothelialization of the nude rat carotid. Response to injury in the absence of functional T lymphocytes.

Authors:  G A Ferns; M A Reidy; R Ross
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

5.  Neointimal formation in two apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility.

Authors:  Weibin Shi; Hong Pei; Joshua J Fischer; Jessica C James; John F Angle; Alan H Matsumoto; Gregory A Helm; Ian J Sarembock
Journal:  J Lipid Res       Date:  2004-08-16       Impact factor: 5.922

6.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

Review 7.  Molecular regulation of vascular smooth muscle cell differentiation in development and disease.

Authors:  Gary K Owens; Meena S Kumar; Brian R Wamhoff
Journal:  Physiol Rev       Date:  2004-07       Impact factor: 37.312

8.  Interferon-gamma inhibits arterial stenosis after injury.

Authors:  G K Hansson; J Holm
Journal:  Circulation       Date:  1991-09       Impact factor: 29.690

9.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

10.  Vascular apolipoprotein e expression and recruitment from circulation to modulate smooth muscle cell response to endothelial denudation.

Authors:  Zachary W Q Moore; Binghua Zhu; David G Kuhel; David Y Hui
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

View more
  34 in total

1.  Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3.

Authors:  Hong Yue; Kuniyoshi Tanaka; Tatsuhiko Furukawa; Sadashiva S Karnik; Wei Li
Journal:  Biochim Biophys Acta       Date:  2012-06-02

2.  TGF-β and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells.

Authors:  Pasithorn A Suwanabol; Stephen M Seedial; Fan Zhang; Xudong Shi; Yi Si; Bo Liu; K Craig Kent
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

3.  Sphingosine-1-phosphate receptor 3 promotes neointimal hyperplasia in mouse iliac-femoral arteries.

Authors:  Takuya Shimizu; Allison De Wispelaere; Martin Winkler; Travis D'Souza; Jacob Caylor; Lihua Chen; Frank Dastvan; Jessie Deou; Aesim Cho; Axel Larena-Avellaneda; Michael Reidy; Guenter Daum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-02       Impact factor: 8.311

Review 4.  Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models.

Authors:  Jennifer Rivera; Christopher G Sobey; Anna K Walduck; Grant R Drummond
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

5.  LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity.

Authors:  Gengze Wu; Jin Cai; Yu Han; Jinghai Chen; Zhan-Peng Huang; Caiyu Chen; Yue Cai; Hefei Huang; Yujia Yang; Yukai Liu; Zaicheng Xu; Duofen He; Xiaoqun Zhang; Xiaoyun Hu; Luca Pinello; Dan Zhong; Fengtian He; Guo-Cheng Yuan; Da-Zhi Wang; Chunyu Zeng
Journal:  Circulation       Date:  2014-08-25       Impact factor: 29.690

Review 6.  A unifying hypothesis for scleroderma: identifying a target cell for scleroderma.

Authors:  William M Mahoney; Jo Nadine Fleming; Stephen M Schwartz
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

7.  Impact of eNOS-Dependent Oxidative Stress on Endothelial Function and Neointima Formation.

Authors:  Tatsiana Suvorava; Nadine Nagy; Stephanie Pick; Oliver Lieven; Ulrich Rüther; Vu Thao-Vi Dao; Jens W Fischer; Martina Weber; Georg Kojda
Journal:  Antioxid Redox Signal       Date:  2015-06-08       Impact factor: 8.401

8.  CD36 Enhances Vascular Smooth Muscle Cell Proliferation and Development of Neointimal Hyperplasia.

Authors:  Hong Yue; Maria Febbraio; Philip A Klenotic; David J Kennedy; Yueheng Wu; Shaoxian Chen; Amira F Gohara; Oliver Li; Adam Belcher; Bin Kuang; Thomas M McIntyre; Roy L Silverstein; Wei Li
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-02       Impact factor: 8.311

9.  HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4.

Authors:  Jingjing Cai; Hong Yuan; Qingde Wang; Huan Yang; Yousef Al-Abed; Zhong Hua; Jiemei Wang; Dandan Chen; Jinze Wu; Ben Lu; John P Pribis; Weihong Jiang; Kan Yang; David J Hackam; Kevin J Tracey; Timothy R Billiar; Alex F Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-10-29       Impact factor: 8.311

10.  Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-α-dependent pathway.

Authors:  Arif Yurdagul; James J Kleinedler; Marshall C McInnis; Alok R Khandelwal; Allyson L Spence; A Wayne Orr; Tammy R Dugas
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.